Anti-viral T-cell Therapy by Gamma Capture

Cytomegalovirus Infections Clinical Trial

— Gamma Capture  

Official title:

Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06027879
• Other study ID #: STUDY23030062
• Status: Enrolling by invitation
• Phase: Phase 1/Phase 2
• Start date: January 8, 2024
• Est. completion date: June 1, 2029

Study information

• Verified date: May 2024
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥1/6 Human Leukocyte Antigens (HLA) -matched, viral specific T cells have efficacy against adenovirus, Cytomegalovirus (CMV), and Epstein Barr Virus (EBV) in subjects who have previously received any type of allogeneic Hematopoietic Cell transplant (HCT) or solid organ transplant (SOT) or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. This trial will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.

Description:

Enrollment for existing UPMC patients.

Ideally, subjects will receive up to ≤1 x 105 (100,000) viable CD3 cells/kg however actual cell dose of infusion will be based upon available cells and subject's clinical picture. Historically, subjects have received all available cells after the gamma capture procedure.

Two-weeks post initial cellular infusion, subject may be eligible to receive additional cellular infusions. If so, either the same or an alternative donor may be considered however, a subject will not receive more than 3 infusions from one donor or exceed 6 infusions in total from all donors. Infusions will be a minimum of 14-days apart. Subjects will not receive additional infusions if they exhibit Graft Versus Host Disease (GvHD) or Cytokine Release Syndrome (CRS) Grade II or higher, according to CTCAE v5.

If a subject is to receive a second infusion, eligibility and baseline data collection will not be repeated for the recipient or original donor, unless necessary per institutional guidelines. Should an alternative donor be selected for an infusion, eligibility of the new donor will need confirmed. Pregnant donors may be considered if medically suitable.

Two weeks post-initial cellular infusion, the following criteria will be assessed to determine if additional infusions are necessary:

• Complete response: Return to normal range as defined by specific assay used and clinical signs and symptoms. These subjects are not eligible to receive an additional cellular infusion.

• Partial response: Decrease in viral load of at least 50% from baseline or significant improvement of clinical signs. The clinical response is further defined as meeting one or more of the following criteria and no worsening in any of the others:

1. Absence of fever, if fever is present at baseline

2. No need for pressors, if on pressors at baseline

3. No need for oxygen and/or mechanical ventilation, if needed at baseline

4. Decrease in stool output, if is diarrhea present at baseline

These subjects may receive additional cellular infusions as clinically indicated:

• Stable disease: Changes insufficient to qualify as partial response or progression. These subjects are eligible to receive additional cellular infusions.

• Progression: Increase in viral load of at least 50% from baseline or dissemination to other sites of disease. These subjects are eligible to receive additional cellular infusions.

Subjects are followed for six months post initial viral-specific T cell infusion. If a subject receives additional infusions, GVHD and adverse events only will be followed for a minimum of three months from last infusion, even if extending beyond the six-month follow-up from the first infusion. Data may be abstracted from subjects' medical charts for an additional 1 year after most recent viral-specific T cell infusion.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 25
• Est. completion date: June 1, 2029
• Est. primary completion date: June 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 65 Years

Eligibility

Inclusion Criteria:

1. Patient, parent, or legal guardian must have given written informed consent, according to FDA guidelines. For pediatric subject who are developmentally able, assent or affirmation will be obtained, if feasible.

2. Male or female, 1 month through 75 years old, inclusive, at the time of informed consent.

3. Prior allogeneic hematopoietic stem cell transplant (bone marrow, peripheral blood stem cells, single or double cord blood), OR prior solid organ transplant (liver, kidney, lung and/or heart, intestinal, or multivisceral), OR diagnosis of primary immunodeficiency OR current/recent administration of immunosuppressive therapy for cancer or autoimmune disease.

4. Negative pregnancy test for females =10 years old or who have reached menarche, unless surgically sterilized. All females of childbearing potential and lactation must agree to use an FDA approved method of birth control for the duration of their participation.

5. Clinical status, at the time of consent, amendable to tapering of steroids to less than 1 mg/kg/day prednisone (or equivalent) prior to cellular infusion.

6. Diagnosis of Adenovirus, CMV, or EBV infection, persistent despite standard therapy.

A. Adenovirus Infection or Disease:

1. Active adenovirus infection: (i.e. gastroenteritis, pneumonia, hemorrhagic cystitis, hepatitis, pancreatitis, meningitis) defined as the demonstration of adenovirus by biopsy specimen from affected site(s) (by culture or histology), or the detection of adenovirus by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents) OR

2. Refractory adenoviremia: defined as DNAemia >5000 copies/mL or <1 log decrease after at least 2 weeks of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents) OR

3. Intolerance of or contraindication to antiviral medications.

B.CMV Infection or Disease:

1. Active CMV infection: (i.e. pneumonia, meningitis, retinitis, hepatitis, hemorrhagic cystitis, and/or gastroenteritis) defined as the demonstration of CMV by biopsy specimen from affected site(s) (by culture or histology) or the detection of CMV by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents) OR

2. Refractory CMV viremia: defined as the continued presence of DNAemia, with =2,000 IU/mL or <1 log decrease after at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents) OR

3. Intolerance of or contraindication to antiviral medications.

C. EBV Infection or Disease:

1. Biopsy proven lymphoma or posttransplant lymphoproliferative disease with EBV genomes detected in tumor cells by immunocytochemistry (i.e. EBER positive) or in situ PCR, OR

2. Clinical or imaging findings consistent with EBV lymphoma and associated elevated EBV viral load in peripheral blood in a patient where biopsy is deemed too high risk, OR

3. Failure of antiviral therapy, as determined by one of the two bullets below after three weeks of anti-CD20 targeted therapy such as Rituximab.

i. There was an increase or less than 50% response at sites of lymphoma disease or lymphoproliferation.

ii. There was a rise or a fall of less than 50% in EBV viral load in peripheral blood of PTLD patients.

Exclusion Criteria:

1. Received Antithymocyte Globulin (ATG) or Alemtuzumab within 28 days of viral-specific T cell infusion and a lack of evidence of T cell survival, defined by <10 CD3+ T cells/uL (in unique situations, plasmapheresis may be considered).

2. Active acute GVHD grades II-IV.

3. Received donor lymphocyte infusion, with the exception of a fraction of an umbilical cord blood, within 14 days of viral-specific T cell infusion. Subjects receiving a fraction of an umbilical cord blood within 14 days of the viral-specific T cell infusion will not be excluded.

4. Active and uncontrolled relapse of malignancy (other than EBV+ post-transplant lymphoproliferative disorder or lymphoma).

5. Received an investigational product in the preceding 2 weeks (prior to infusion) that may impact Viral Specific T-cells (VST) survival.

6. Females of child bearing potential must not be lactating.

7. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks to participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.

Related Conditions & MeSH terms

• Adenovirus
• Communicable Diseases
• Cytomegalovirus Infections
• Epstein-Barr Virus Infections
• Infections

Intervention

Biological:
• Specific T- Lymphocytes
Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

Locations

Country	Name	City	State
United States	UPMC Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Paul Szabolcs

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grade III-IV Acute GvHD	The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.	Day 0
Primary	Grade III-IV Acute GvHD	The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.	1 month from first cellular infusion
Primary	Grade III-IV Acute GvHD	The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.	3 month from first cellular infusion
Primary	Grade III-IV Acute GvHD	The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.	6 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Elimination or reduction of oxygen dependence identified at baseline	1 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily	1 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of fever, attributable to viral disease	1 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of radiographic findings attributable to viral disease	1 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis	1 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Elimination or reduction of oxygen dependence identified at baseline	3 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily	3 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of fever, attributable to viral disease	3 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of radiographic findings attributable to viral disease	3 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis	3 month from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Elimination or reduction of oxygen dependence identified at baseline	6 months from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily	6 months from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution of fever, attributable to viral disease	6 months from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of radiographic findings attributable to viral disease	6 months from first cellular infusion
Primary	Clinical response to treatment of viral infection	Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis	6 months from first cellular infusion
Secondary	1-year overall survival from first cellular infusion (continuous)	Number of deaths that occurred from treatment	First cellular infusion to 1 year post first cellular infusion
Secondary	Incidence of Graft rejection	How frequent, if any, graft rejection occurs	3 months after last cellular infusion
Secondary	Incidence of Graft rejection	How frequent, if any, graft rejection occurs	6 months after last cellular infusion
Secondary	Incidence of Mechanical ventilation exceeding 48 hours	How long, if any	3 months after last cellular infusion
Secondary	Incidence of Mechanical ventilation exceeding 48 hours	How long, if any	6 months after last cellular infusion
Secondary	Usage of concomitant antiviral agents	The introduction of concomitant antiviral medication post infusion, if any	First cellular infusion to 1 year post first cellular infusion
Secondary	Immune reconstitution with focus on adaptive T cell immunity and viral-specific responses	The pace of systemic immune reconstitution, measured by the increased number of CD4+ T lymphocytes.	1 month following first cellular infusion
Secondary	Immune reconstitution with focus on adaptive T cell immunity and viral-specific responses	The pace of systemic immune reconstitution, measured by the increased number of CD4+ T lymphocytes.	3 months following first cellular infusion
Secondary	Incidence of severe or extensive chronic GVHD	The number of patients who develop chronic graft versus host disease (GVHD) post first infusion based on Clinical Chronic GvHD Assessment	6 months from first cellular infusion